Though costly, blood cancer drugs appear cost-effectiveFebruary 8, 2015Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacyCMLNon-Hodgkin Lymphoma
EC supports continued use of ponatinibJanuary 21, 2015Leukemia, Myelodysplasia, TransplantationPharmacyALLCML
NHS cuts 5 blood cancer drugs from CDF, adds 1January 14, 2015Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacyRelated IssuesCMLNon-Hodgkin Lymphoma
Finding could help docs tailor treatment for myeloid leukemiasDecember 9, 2014Leukemia, Myelodysplasia, TransplantationAMLCML
Discovery reveals potential approach to treat CMLNovember 20, 2014Leukemia, Myelodysplasia, TransplantationCML
Compounds could treat CML more effectivelyNovember 11, 2014Leukemia, Myelodysplasia, TransplantationCML
Study explains BCR-ABL-independent imatinib resistanceSeptember 4, 2014Leukemia, Myelodysplasia, TransplantationCML
Switch to nilotinib improves deep molecular response in CMLJune 19, 2014Leukemia, Myelodysplasia, TransplantationCML
FDA approves CML drug for home administrationMay 6, 2014Leukemia, Myelodysplasia, TransplantationPharmacyCML
Cell adherence linked to treatment resistance in CMLMarch 14, 2014Leukemia, Myelodysplasia, TransplantationCML
Omacetaxine mepesuccinate gets full FDA approvalFebruary 16, 2014Leukemia, Myelodysplasia, TransplantationPharmacyCML
Affluence seems to affect CML survival in the UKFebruary 5, 2014Leukemia, Myelodysplasia, TransplantationCML
Out-of-pocket costs hinder adherence to imatinibJanuary 8, 2014Leukemia, Myelodysplasia, TransplantationPharmacyCML
